I S S N 2 3 6 4 - 2 351 | A 6 0 711 | Interview ’s Paul Greenland talks European about the launch Life Sciences and of the first mAb Industry Magazine biosimilar and the new challenges in Biotechnology Summer Edition 2015 | Volume 14 | 20 € development.

Financing European biotech companies have added crowdinvesting to the fi nancing toolbox Nagoya Protocol Poor implementation of benefi t sharing could block Tracking biotech innovation in Europe Antibiotics New EU fi nancing instrument to close funding gap in high- stealthy risk antibiotic development EuroBioFairsCompass The unique guide to the top life killers sciences events in the second half of 2015 FREE EXCERPT

Liquid Biopsy

4 CONTENTS European Biotechnology | Summer Edition | Vol. 14 | 2015

FREE EXCERPT

COVER STORY INSIGHT EUROPE REGIONAL NEWS

6 European Commission opens 42 Northern Europe: fl oodgates for GM imports Sweden, Denmark, Finland, and Norway 10 First genome-edited crops to be stamped non-GMO by Member 44 Western Europe: States; Heard in Brussels France, Belgium, The Netherlands and the UK 12 European Commission and Euro- pean Investment Bank set to 46 Central Europe: launch new fi nancing instrument Austria, Germany and Switzerland for high-risk antibiotics develop- ment; Horizon2020 call focuses 48 Southern Europe: on personalised medicine; UK lags Italy, Spain, Portugal, Cyprus & Malta behind EU in fi ght against cancer; MEPs demand no dilution of EU life 50 Eastern Europe: sciences rules through TTIP Poland and the Czech Republic

ECONOMY PICK & MIX

22 Interview: Paul Greenland, 51 Expert conference on Hospira Vice President of Biologics progress made in marine biodiscovery 14 25 Update on clinical trials SCIENCE & TECHNOLOGY 28 DIA Euromeeting defi nes upcoming Fishing malignancy challenges in healthcare: ATMPs, 56 Toxins for fi ghting cancer personalised meds, and biosimilars from the stream 57 Bioengineers take protein A hurdle 29 EMA News For over a century, oncologists have 58 3D cancer biobank screening struggled to understand how cancer 30 IPO update: EU companies go gives insights into drug resistance develops resistance to treatments. Now west, US biotech goes east; IP Flash novel ultrasensitive techniques that allow SERVICE them to track cancer mutations and cir- 31 Analyst commentary culating tumour cells in the bloodstream 82 Biopeople are raising hopes that testing could soon 32 Euro Biotech Stocks detect initial signs of tumour resistance 83 News from partner associations: and response to treatment, as well as reli- 34 Start-up stories: Swecure AB EBN; SBA; BIO Deutschland; DIA ably predict therapy outcomes. Though Stockholm & Gothenburg it’s early days yet, Life Sciences and Big 88 Events Pharma fi rms are partnering to validate 40 Interview: Ernesto Bertarelli, 89 New products; Company index liquid biopsy methods in clinical trials. Co-Chair, Bertarelli Foundation 90 Encore

IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: [email protected], Internet: www.eurobiotechnews.eu; Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co- editor), Uta Mommert, Dr Martin Laqua, Julie Colthorpe, Dr Bernd Kaltwaßer; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49- 30-2649-2154; Distribution: Marcus Laschke, +49-30-2649-2148; Printed at: H. Heenemann GmbH & Co. KG; Graphic Design: Michaela Reblin. European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 80.00, Students € 40.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the pub- lisher. Supplements: EBD Group, BIOCOM AG/DECHEMA. Cover Photo: © kikkerdirk, fotoliaxrender, vege/fotolia.com. ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany. European Biotechnology | Summer Edition | Vol. 14 | 2015 CONTENTS 5

FREE EXCERPT

FINANCE BIODIVERSITY EDITORIAL

Fundraising with The challenges Innovation has always challenged soci- schools, not sharks ety and law – and vice versa. The lat- est and most ambiguous case has In the past several months, Life Sciences been the intervention in human germ companies all over Europe have suc- lines with genome editing. In May, EU cessfully capitalised on crowdinvesting and US policymakers underscored the schemes. EURO BIOTECH introduces the importance of upholding the current most relevant campaigns and summa- ban (see p. 3) after Chinese research- rises the prevailing business models of ers revealed failed testing in the area high-fl ying platforms. on non-viable embryos. But what if it had worked? Is a ban acceptable if you could save an embryo with a le- thal gene defect? Other modern quan- daries are being posed by biotech 52 breeds derived from techniques so new that they’re not covered by cur- rent EU law (p. 10). Balancing out the Limits are easier to set in emerging fi elds like liquid biopsy, where blood Nagoya Protocol could soon tell us which cancer thera- pies are most appropriate (see p. 14). The EU’s regulation for the implementa- EURO BIOTECH asked industry leaders tion of the Nagoya Protocol is seeking about the best ways to validate the ap- to establish a clear access and benefi t- proach. They told us implementation sharing regime, but scientists and indus- was key – just like their counterparts in 36 try leaders are highly concerned about the area of biodiversity legislation, certainty and clarity. where the Nagoya Protocol is set to take effect (p. 52). Fortunately, there are plenty of areas where society can still count on re- turns from innovation, and innovators SPECIAL on plenty of reinvestment (p. 12, 36). Making innovation perceptible to society is crucial to maintaining a EU Event Compass viable life sciences sector in Europe. 61 Navigating conferences And only that acceptance will help us 62 Nordic Life Science Days, Stockholm strike the right balance between regu- 64 4th Conf. on CO as Feedstock for lation and scientifi c freedom. 2 Fuels, Chemistry, Polymers, Essen 66 European Biotech Week 68 BioJapan 2015, Yokohama 70 Bioinnovation, Gdansk 72 BIO-Europe, Munich 74 DIA Europ. Biosimilar Conf., London 76 PharmaLab Congress, Neuss 78 3rd International mRNA Health Conference, Berlin Thomas 80 EuroPLX Pharma Partnering Gabrielczyk Conference, Athens Editor-in-Chief 10 INSIGHT EUROPE European Biotechnology | Summer Edition | Vol. 14 | 2015

FREE EXCERPT

No-GMO wave Heard in Brussels

AGRIBIOTECH In 2012, the EU’s “New Nagoya – protecting resources with paperwork Techniques Working Group” (NTWG) submitted its fi nal report on novel biotech BRUSSELS European October and has to methods for genetic manipulation of crops Biotechnology Net- be implemented. to the European Commission. Its report in- work had the good And when I say im- vestigated if crops designed by novel tools fortune to moderate plemented, I mean such as genome editing or gene silenc- the 8th Berlin Confer- into all legal systems, ing, are GMOs that must be approved and ence on IP in Life Sci- and Europe has many safety assesed under EU law. However, ence, which this year more of those than until now, the Commission had not made had a focus on nat- a simple headcount a political decision on the matter. The US ural products. “That of countries. Spain is company Cibus has now created prece- will be interesting,” my favourite example, dents. In Germany it has already received I thought to myself, where Nagoya will be deregulated status for its herbicide-toler- thinking about the implemented by each ant “SU canola” from the federal authori- world of complex of the 17 autonomous ty BVL. This means, that Cibus can imme- structures and chal- communities. So, sam- diately plant and market its crop without lenging development CLAIRE SKENTELBERY pling natural resourc- any need to label it as a GMO. The com- pathways. “Interest- Secretary General of the Euro- es in Spain (including pany has also fi led for deregulated state in ing” soon paled into pean Biotechnology Network those found in marine Spain, Sweden, Finland, Ireland and the insignifi cance as I fell ecosystems) could in- UK in order to safe up to US$15m for an headlong into the tiger trap that is the volve discussions with ALL the regions in EU GMO approval. In March, the German Nagoya Protocol, coming soon folks to which your bacteria, nematode or plant Agriculture Ministry rejected objections a country near you. can be cultivated, and that is a lot of pa- by anti-GMO campaigners from Testbio- For those of you uninitiated in such perwork in a wide variety of dialects. tech who claimed Cibus method was GM. matters, the Nagoya Protocol is a global Europe is woefully underprepared If other regulators follow the German ex- programme with the extremely relevant for the level of stringency required by ample, a wave of genetically engineered intention to regulate access to genetic re- Nagoya, most countries aren’t ready for “no-GMOs” are set to enter the bloc. sources and ensure the sharing of bene- October because they didn’t pay atten- fi ts arising from their utilisation. Europe, tion when they should have, which will Using natural gene repair as we recall, knows a thing or two about result in the usual amusing quagmire ‘accessing’ resources from countries be- that Europe is good at creating. If this Cibus‘ canola has been genetically engi- yond its immediate vicinity without the sounds fl ippant, perhaps it is, but this neered by targeted mutagenesis. Its does express written consent of their owners column comes in the light of the fact not contain any foreign DNA sequence and Nagoya is a worthy platform to pre- that research into, and commercialisa- such as GMOs. In contrast, the compa- vent sticky-fi ngered organisations from tion of natural products has collapsed ny uses so-called gene repair oligonu- literally vacuuming up local resources in the years that have seen increasing cleotides (GRON) to inactivate the crop’s and knowhow without a) the locals’ regulation on access, with, I recall, a re- acetolactat synthase (ALS) gene: in a fi rst consent and b) full engagement fi nan- duction of the big companies active in step a GRON pairs with a complimenta- cially and culturally. natural products declining from 13 to 3 ry target sequence in the ALS gene. How- This all sounds great and, as usual, (don’t quote me on that exact number ever, as the GRON differs only in one or the liberation of keen regulators but it is close). two nucleotides, mismatches in the crop’s around the world has ensured that it The irony is that you only have to DNA occur that are corrected by gene re- is now massively complicated and is step outside your back door to fi nd suf- pair enzymes. Afterwards, the GRONs already protecting local resources by fi cient genetic resources to last a life- are completely digested and the ALS gene ensuring that nobody can be bothered time of natural product research. You then contains an inactivating mismatch to fi ll in all the forms to pick a plant don’t have to go to anywhere exotic mutation. As the GRON is transient and or sample the water (see p. 52). This (and fi ll in lots of forms) and European the product is indistinguishable from con- learned column however wants to implementation of Nagoya will prob- ventionally mutated crops, the BVL and focus on what happens when Nagoya ably ensure that we all look closer to NTWG say it is not a GMO. The same ap- arrives in Europe, which it will do in home in the future. 

plies to genome edited crops.  Picture: EBN 14 Cover STORY European Biotechnology | Spring Edition | Vol. 14 | 2015

With the Cluster-Chip, researchers were able to detect tumour-cell clusters in the blood of 30% of the breast cancer patients they tested. Monitoring these potentially metastasis-inducing cells can help improve diagnosis. European Biotechnology | Summer Edition | Vol. 14 | 2015 Cover STORY 15

FREE EXCERPT Needles in haystacks

Liquid Biopsy Detection of minimal residual disease in cancer patients who have undergone sur- gery and first-line therapy has become the next big goal for oncologists. Until now, it’s been impossible to detect the few tumour cells in the blood that manage to escape treatment and eventually lay the foun- dation for deadly metastases,­ therapy resistance and relapse. However, recent advances in the area of liquid biopsy suggest that new analytical tools able to identify circulating tumour cells may soon open the door to serial blood analyses to guide personalised treatments and predict therapy outcomes.

verything seemed to be back on RNAs (miRNAs) can be used to detect min- high numbers of CTCs in the blood corre- the right track for Sophie follow- imal residual disease (MRD) and predict the late with a bad prognosis is documented ing several cycles of chemo- and probability for distant metastases, it would for breast cancer, meta­static relapse and targeted therapy. “Her tumour accomplish a task that neither radio­logical progression in prostate, lung, and color- shrankE like ice in the sun. It completely disease monitoring nor analysis of tissue ectal cancer. That’s why liquid biop­sy as a disappeared,” says her mother. What the biopsies has been able to solve so far. Re- method for tracking the molecular evolu- schoolgirl’s doctors couldn’t see was that cent research results suggest that liquid bi- tion of tumours has begun to draw major a few tumour cells that didn’t respond opsy can detect development of resistant attention in pharma companies. to treatment had broken away from her tumour cells up to ten months earlier than primary tumour and entered her blood- radiological methods can. Evidence that Trying to make biopsies stream. Nine months after her initial treat- a thing of the past ment, a relapse killed her. Globally, more than 95% of all cancer ”The problem with solid tumours is that deaths occur after relapse. And circulat- bio­psies don’t allow us to track changes in ing meta­stasis initiator cells (MICs) – which the tumour’s molecular properties, such as enter distant organs from the bloodstream mutations that lead to therapy­-resistant cell and form new tumours – cause them. Can- clones,” says Thomas Schlange, Global cer specialists therefore view identifica- Biomarker Research at Bayer HealthCare tion and destruction of MICs in the blood- in Wuppertal. ”Biopsies are often difficult stream as an essential step towards getting to obtain, and they are also burdensome on top of the disease. The problem is that for the patient. They thus can’t be taken we still don’t know enough about the mo- Thomas Schlange serially to check response to targeted ther- lecular characteristics of those cells, or Bayer HealthCare, Wuppertal apies. Liquid biop­sy provides the opportu- how they evolve. nity to see a given tumour’s full molecular Technological advances over the past What do liquid biopsy methods hetero­geneity, and to follow its changes two decades are starting to change that by ? promise? over time,” he adds. paving the way for liquid biopsy – the sys- Although most technologies aimed at tematic detection and analysis of circulat- Finding biomarkers through a isolating CTCs and profiling their muta- ing tumour cells (CTCs), needles in a hay- ! simple blood sample that shows tions, gene and protein expression have stack made up of billions of normal blood us if a cancer therapy actually works been in development for less than 20 cells. Among researchers and life sciences would improve the situation for both years, and have only been validated in companies, excitement is growing as evi- patients and drug developers. It small clinical trials, interest in the area is dence mounts that a simple blood draw is would allow us to follow the disease high. More and more companies are edg- now able to reveal whether a therapy has and adapt therapy individually over ing into the liquid biopsy market, includ- actually worked or not. The potential im- time. Today, we have one CTC-based ing pharma heavy­weights like J&J, Lilly, pact for patients is high. If CTCs, circulat- prognostic tumour test. In the future, ing tumour DNA (ctDNA) or vesicle-coat- we aim to have predictive tests. ›› Read the full story in the

Picture: MGH. Georgia Tech (left), Bayer Healthcare (right) ed mRNA and – most exploratory – micro printed issue. 22 ECONOMY European Biotechnology | Summer Edition | Vol. 14 | 2015

FREE EXCERPT Fighting for access

BIOSIMILARS The  rst monoclonal antibody biosimilar reached the European market this year, and Hospira was in on the action. Over the last seven years, the company had already launched two copycat versions of biologics. Paul Greenland, VP of the biologics division at Hospira, talks about what it takes to launch a biosimilar on the European market.

EuroBiotech_It was just a matter of hours fore, the uptake is really dependent on after J&J’s Remicade (in iximab) patent initially getting clinician agreement that expired before the first biosimilars, they want to use a biosimilar. And obvi- among them Hospira’s In ectra, hit the ously, that takes some time. European markets. How was the launch for you? EuroBiotech_How will the in iximab bio- Greenland_It has been a fantastic few similar fare in comparison to the EPO weeks, or months rather, for Hospira. and G-CSF biosimilars? When the biosimilar was approved by Greenland_I think infliximab will lie the EC back in September 2013, we were somewhere in between the two. Exactly only able to launch on some of the small- where, well, that is diffi cult to say. We are er markets due to patent restrictions. So obviously hoping that it will be closer to the real excitement came in February this 70%, and all our efforts are to try and year, when the patents lifted in most of make sure the uptake is as fast as possi- the major European markets. It has been ble. a very busy few weeks. EuroBiotech_Reportedly, there is some EuroBiotech_The biosimilar market must skepticism prevalent among healthcare be quite pro table! PAUL GREENLAND is Vice Presi- workers where bio similars are con- Greenland_It’s certainly a very attractive dent Biologics at Hospira UK. He has cerned. Why do you think that is? market. The size of the Remicade market been responsible for the launch of Greenland_There is certainly a lack of un- before the biosimilars came was over Hospira’s three European biosimilar derstanding as to what biosimilars are. A €2bn. So the market is big enough for sev- products Retacrit (epoetin zeta), biosimilar is only a biosimilar because it eral infl iximab biosimilars: Celltrion mar- Nivestim ( lgrastim) and In ectra has gone through a certain regulatory kets Remsima while we have launched In- (in iximab). Greenland is an active pathway. The product itself is actually a fl ectra in all European markets. member of the European Biosimilars biologic, just like other biologics. It is Group (EBG) and chairs their Biosim- manufactured in exactly the same way as EuroBiotech_Small-molecule generics ilars Market Access Group (EBG- the originator biologic. It’s approved for can take up to 90% of a market within MAG). use like any other biologic, and it controls months of a launch. What is the situa- for quality like any other biologic.Some- tion like for biosimilars? times people assume that biosimilars are Greenland_The uptake for biosimilars is actually different types of molecules to different from the uptake you would ex- tration. But that does not happen over- the originators. But they are not! They are pect for generics. It’s a much slower, night or nearly as dramatically as it would just being approved slightly differently. steadier uptake. From our experience do with a generic. This is mainly because We have also seen that in actual fact, with biosimilars, we know that the up- there is no general agreement across Eu- there is a lack of understanding on bio- take can differ considerably. For exam- rope on pharmacy level substitution. In logics in general among physicians: […] ple, our EPO biosimilar achieved 40% most countries in Europe, pharmacy-level market share, while our G-CSF biosimilar substitution is discouraged for all biolog- ›› Read the full interview in the

is at more than 70 percent market pene- ics products, not only biosimilars. There- printed issue. Pictures: Hospira UK 36 Finance European Biotechnology | Summer Edition | Vol. 14 | 2015

Democracy at work in biotech financing

Crowdinvesting The past six months saw many European life sciences companies successfully cashing in substantial amounts to bring their businesses forward. In comparison, the almost €1m (£0.7m) for British Cell Therapy, exactly €1m for German Riboxx and €1.07m for French Eyebrain look meagre at best. Under close scrutiny, however, they could point to a revolution in the making: the money has been raised via crowdinvesting, a new funding source that is rapidly gaining traction in Europe’s notoriously under-financed biotech world.

›› Read the full story in the printed issue. Picture: vilainecrevette/fotolia.com 52 Policy European Biotechnology | Summer Edition | Vol. 14 | 2015

FREE EXCERPT

Lost in translation

Biodiversity Last October, the Nagoya Protocol entered into force for all signing parties as an international agreement aimed at sharing the benefits arising from the utilisation of genet- ic resources in a fair and equitable way. As a signing partner, the EU has now passed a regula- tion that will enter into full force in October. Some European scientists and industry leaders have raised concerns that the regulation is too vague, and say that – at least initially – it will only breed confusion. Despite the challenges, many companies are already trying to develop best practices that stick to the letter and spirit of the agreement.

›› Read the full story in the printed issue. Picture: silencefoto/fotolia.com European Biotechnology | Summer Edition | Vol. 14 | 2015 COMPANY INDEX/PRODUCTS 89

FREE EXCERPT

3P Biopharmaceuticals S.L. (ES) ...... 49 Iproteos SL (ES) ...... 37 AbbVie Inc. (USA) ...... 26, 31 Isarna Therapeutics GmbH (GER) ...... 27 Ablynx NV (B) ...... 26, 85 Janssen Biologics B.V. (NL) ...... 26, 85 Eternal stability Adiuvo Investment S.A. (PL) ...... 50 Johnson & Johnson (USA) ...... 15 Aerie Pharmaceuticals (USA) ...... 31 Joint Polish Investment Fund ...... 50 Aerocrine AB (SE) ...... 45 Juno Therapeutics (USA) ...... 47 CANDOR By improving the diluent for Aescuvest (GER) ...... 38 Kite Pharma (USA) ...... 47 Agilent Technologies (USA) ...... 16 Lanthio Pharma B.V. (NL) ...... 47 long-term storage of conjugates of horse- Alan Boyd Consultants Ltd. (UK) ...... 82 Laracompanion (GER) ...... 38 Alexion Europe SAS (F) ...... 31 Larodan Fine Chemicals (SE) ...... 82 radish peroxidase (HRP), Candor was able Algo-Source Technologies ...... 45 Lavazza (I) ...... 49 to enhance their stability and activity. (F) ...... 31 LEO Pharma A/S (DK) ...... 42 Almirall S. A. (ES) ...... 49 Life Science Austria LISA (A) ...... 11 Conjugates of antibodies or Neutravidin/ Antabio (F) ...... 37 Lundbeck A/S (DK) ...... 82 arGEN-X B.V. (NL) ...... 26, 42 Lytix Biopharma A/S (N) ...... 42 Streptavidin, diluted in HRP-Protector™, AstraZeneca AB (SE/UK) ...... 16, 26, 42, 44, 47, 85 MARSA Corporate Finance GmbH (CH) ...... 84 can be stored over a long period of time. BASF (GER) ...... 6, 44, 46 MediGene AG (GER) ...... 25, 47, 85 Bavarian Nordic A/S (DK) ...... 43 Medimmune Ltd (UK) ...... 26 Conjugate stability is also maintained over Bayer AG (GER) ...... 6,15, 46, 47 Merck & Co. (USA) ...... 26 Berna Biotech AG (CH) ...... 82 Merck KGaA (GER) ...... 25, 40 several years in low-concentrated ready- BIO.NRW (GER) ...... 85 Merck Serono (CH) ...... 25, 16 to-use solutions (40–500 ng/ml). Like the Biobag GmbH (GER) ...... 44 Merck Serono Ventures (CH) ...... 85 BIOCOM AG (GER) ...... 37, 61 Merozyne Therapeutics AB (SE) ...... 43 previous formulation, the new HRP-Pro- Idec (USA) ...... 26 Mitotech SA (LUX) ...... 26 Bioinnovation Summit (PL) ...... 71 Monsanto (USA) ...... 46 tector is also an exceptional assay diluent. BionNTech GmbH (GER) ...... 47 MorphoSys AG (GER) ...... 26 Bionos Biotech (ES) ...... 49 mRNA Conference Berlin 2015 (GER) ...... 78, 79 HRP-Protector is ready-to-use and avail- Biostartr (GER) ...... 39 MSD (USA) ...... 85 able in bottle sizes of 50 ml (order number Biotec (IRL) ...... 44 Mypharmacompany (GER) ...... 38 Biovest Europe Ltd. (UK) ...... 29 Nepentex (PL) ...... 50 222 050), 125 ml (order number 222 125) Boehringer Ingelheim (GER) ...... 16, 25 Nestle Health Science SA (CH) ...... 47 Bristol-Myers Squibb (USA) ...... 25, 26, 29 Neurimmune AG (CH) ...... 26 and 500 ml (order number 222 500). The CANDOR Bioscience GmbH (GER) ...... 89 Newron Pharmaceuticals S.p.A. (I) ...... 49 former formulation is still available upon Capital Cell (ES) ...... 38 Nordic Life Science Day 2015 (SE) ...... 62, 63 Capp Medical (USA) ...... 19 Nordic Nanovestor ASA (N) ...... 43 request. The order numbers have re- Celgene Europe Ltd. (UK) ...... 29, 44 nova-Institut GmbH (GER) ...... 64, 65 Celltrion (USA) ...... 22 Novamont S.p.A. (I) ...... 44, 49 mained 220 050, 220 125, and 220 500. Cevec Pharma GmbH (GER) ...... 82 Novartis AG (CH) ...... 44, 84 China Medical Systems Holding Ltd ...... 43 NovImmune S.A. (CH) ...... 47 Cibus Inc. (USA) ...... 10 Novo Nordisk A/S (DK) ...... 26, 82 Circassia Ltd. (UK) ...... 45 Oncolytics Biotech (UK) Ltd ...... 29 Coca-Cola (USA) ...... 90 OPIS s.r.l. (I) ...... 27 Comdis (GER) ...... 61 Oracle Health Science ...... 28 CONCEPT HEIDELBERG (GER) ...... 76, 77 Orexo AB (SE) ...... 31 Coretherapix (ES) ...... 49 Oryx Therapies (GER) ...... 47 Crispr Therapeutics (CH) ...... 82 Perstorp AB (SE) ...... 44 Daiichi Sankyo Europe GmbH ...... 29 Pfi zer Inc. (USA) ...... 25 Datamonitor (UK) ...... 26 Pharmacyclics Inc. (USA) ...... 31 Debiopharm S.A. (CH) ...... 26 Pharmium Securities (F) ...... 31 Dentons Europe LLP (GER) ...... 9 Pioneer Hi-Bred International Inc. (USA) ...... 6 Deutsche Messe AG (GER) ...... 23 Pliva Hrvatska d.o.o. (HR) ...... 82 DIA Europe / DIA Home (CH) ...... 74, 75 Prosonix plc (UK) ...... 45 Dow Chemicals (USA) ...... 46 Prostalund (SE) ...... 82 DuPont (USA) ...... 6 Prothena Biosciences Inc. (USA) ...... 31 EBD Group (CH/USA) ...... Supplement, 72, 73 Qiagen (GER) ...... 85 eCOAST Marine Research (B) ...... 54 QIAGEN NV (GER) ...... 16, 17 Edmond de Rothschild Investment Partner (F) ...... 38 RauCon EuroPLX (GER) ...... 80, 81 Eli Lilly (USA) ...... 15, 47 Regeneron Pharmaceuticals Inc. (USA) ...... 27 Epitherapeutics (DK) ...... 42 Rhein Biotech GmbH (GER) ...... 82 Eppendorf AG - Bioprocess Center Europe (GER) ...... 13 Riboxx GmbH (GER) ...... 36 EuropaBio/EuropeanBiotechWeek (B) ...... 66, 67 Roche AG (CH) ...... 16, 25, 26, 44, 56, 85 European Biotechnology Network (B) ...... 60 Sangamo Biosciences Inc. (USA) ...... 3 Europackaging (UK) ...... 44 Sanofi SA (F) ...... 27, 29, 54 Evolva A/S (CH) ...... 53, 54 SARomics Biostructures (SE) ...... 43 Exini Diagnostics (SE) ...... 82 Scancell Holding plc. (UK) ...... 25 Exosome Diagnostics GmbH (GER) ...... 16 Scil Proteins GmbH (GER) ...... 82 ExpreS2ion Biotechnologies (DK) ...... 26 Serendipity Innovations AB (SE) ...... 34 EY (GER) ...... 46 Serono International SA (CH) ...... 40 Eyebrain Sarl (F) ...... 36 Sinvestec (UK) ...... 44 Faron Pharmaceuticals Ltd. (FI) ...... 43 Stage Cell Therapeutics GmbH (GER) ...... 47 Forbion Capital Partners (NL) ...... 85 Sterne, Kessler, Goldstein & Fox (USA) ...... 29, 35 Fuchs Europe Schmierstoffe GmbH...... 44 Swecure AB (SE) ...... 34 More than 850 customers in 50 countries Genzyme Corp. (USA) ...... 82 Swedish Orphan Biovitrum AB (SE) ...... 43 Gilead Ltd. (USA) ...... 31, 42 Synageva BioPharma Ltd. (USA) ...... 31 use Candor products and benefit from Gilupi GmbH (GER) ...... 18 Syndicate Room (UK) ...... 38 GlaxoSmithKline (UK) ...... 48, 82 Syngenta AG (CH) ...... 46 the company’s expertise in assay deve- GNA Biosolutions GmbH (GER) ...... 50 T-Cell Factory B.V. (NL) ...... 47 lopment and sample measurement. Grifols S.A. (ES) ...... 48 Taconic Biosciences (USA) ...... CP2 High-Tech Gründerfonds Management GmbH (GER) . . . 19 Thermo Fisher Scientifi c (USA) ...... 7,16, 20, 21 Hospira (UK) ...... 22, 24, 28 Thrombogenics (B) ...... 31, 45 Hospira One 2 One Global Pharmaceutical (USA) . . . . CP4 Trianta Immunotherapies GmbH (GER) ...... 25 CONTACT ICS Convention Design, Inc. (JP) ...... 68, 69 uniQure BV (NL) ...... 31, 48 Illumina Inc. (USA) ...... 16 Vanda Pharmaceuticals Ltd. (USA) ...... 29 Candor Bioscience GmbH Immunocore Ltd. (UK) ...... 25, 44 Veridex LLC (USA) ...... 16 Simoniusstrasse 39 ImmunoGen Corp. (USA) ...... 29 Vetter Pharma (GER) ...... 25, 82 Immunothep SA (PT) ...... 48 Vossius & Partner (GER) ...... 54 88239 Wangen, Germany IMS Health (UK) ...... 90 Wacker Biotech GmbH (GER) ...... 82 Inivata (UK) ...... 19 ZAB Brandenburg Economic Development Board (GER) . CP3 Tel.: +49(0)-7522-7952-70 Inkemia (ES) ...... 49 Zealand Pharmaceuticals A/S (DK) ...... 26, 31 Fax: +49(0)-7522-7952-729 Innate Pharma SAS (F) ...... 44 Zeclinics SL (ES) ...... 38

Picture: Candor Innovia Films Ltd. (UK) ...... 44 ZINSSER ANALYTIC GMBH (GER) ...... 41 www.candor-bioscience.com Life Sciences. Living Research. Berlin. Brandenburg.

A vibrant network.

Berlin-Brandenburg is one of Europe´s leading locations for the Life Sciences. It is also an R&D FDSLWDO WKDW PDJQHWLFDOO\ DWWUDFWV WKH ZRUOGV WRS VFLHQWLVWV +HUH \RXOO ¿QG DWWUDFWLYH IXQGLQJ conditions, close link-ages between business and science, the highest concentration of R&D LQ(XURSHDG\QDPLFVWDUWXSVFHQHDQGDPXOWLIDFHWHGHQWUHSUHQHXULDOHQYLURQPHQWPDGHXSRI PRUHWKDQSKDUPDFHXWLFDOELRWHFKDQGPHGLFDOWHFKQRORJ\FRPSDQLHV&RPHGLVFRYHUWKLV one-of-a-kind landscape for scientists and entrepreneurs.

www.healthcapital.de/en

Get in touch with us @BIO 2015 I Philadelphia German Pavilion | Booth 1013-01

Investition in Ihre Zukunft! EUROPÄISCHE UNION Funded by the federal state of Berlin, the federal state of Brandenburg

Europäischer Fonds für DQG WKH ,QYHVWLWLRQVEDQN %HUOLQ FRIXQGHG E\ WKH (XURSHDQ 8QLRQ Regionale Entwicklung (XURSHDQ)XQGIRU5HJLRQDO'HYHORSPHQW ,QYHVWLQJLQ\RXU)XWXUH

210x275_Motiv_Life_Science_eng_EBN_BIO15.indd 1 20.05.2015 16:03:10 THE POWER OF COMPLEMENTARY CAPABILITIES

GLOBAL REACH | SECURITY OF SUPPLY | EFFICIENCY

Biologics & small molecule fill & finish

Clinical & commercial supply to 45+ local markets

On-site development and bio-analytical expertise Zagreb, Croatia Liscate, Italy NORTH AMERICA Advanced lyophilization capabilities EUROPE McPherson, USA Flexible labeling and packaging

Cold chain management

QP Release services

Let’s talk KNOWLEDGE | EXPERIENCE | EXPERTISE Call +1-224-212-2267 or +44 (0) 1926 835 554 or e-mail [email protected]

Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045 P14-0381-7-8.25x10.875-Aug., 14

EB_Spring_2015_Hospira_210x275.indd 1 27.02.2015 10:07:35 Uhr